Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) yesterday and set a price target of $40. The company’s shares closed yesterday at $28.80.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.3% and a 55.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Adverum Biotechnologies.
Currently, the analyst consensus on Rhythm Pharmaceuticals Inc is Moderate Buy and the average price target is $38, representing a 31.9% upside.
In a report issued on June 15, Needham also maintained a Buy rating on the stock with a $36 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $34.99 and a one-year low of $16.80. Currently, Rhythm Pharmaceuticals Inc has an average volume of 137.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
